DK3762004T3 - Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor - Google Patents

Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor Download PDF

Info

Publication number
DK3762004T3
DK3762004T3 DK19710999.4T DK19710999T DK3762004T3 DK 3762004 T3 DK3762004 T3 DK 3762004T3 DK 19710999 T DK19710999 T DK 19710999T DK 3762004 T3 DK3762004 T3 DK 3762004T3
Authority
DK
Denmark
Prior art keywords
cdk4
tumors
inhibitor
treatment
combination
Prior art date
Application number
DK19710999.4T
Other languages
English (en)
Inventor
Per Sonne Holm
Roman Nawroth
Original Assignee
Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Rechts Der Isar Der Technischen Univ Muenchen filed Critical Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Application granted granted Critical
Publication of DK3762004T3 publication Critical patent/DK3762004T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19710999.4T 2018-03-05 2019-03-05 Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor DK3762004T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
DK3762004T3 true DK3762004T3 (da) 2023-11-27

Family

ID=61569019

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19710999.4T DK3762004T3 (da) 2018-03-05 2019-03-05 Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor

Country Status (13)

Country Link
US (1) US20210038661A1 (da)
EP (1) EP3762004B1 (da)
JP (2) JP2021517119A (da)
KR (2) KR20210031852A (da)
CN (1) CN112533620B (da)
AU (1) AU2019232768B2 (da)
CA (1) CA3092907A1 (da)
DK (1) DK3762004T3 (da)
ES (1) ES2965632T3 (da)
FI (1) FI3762004T3 (da)
HU (1) HUE064471T2 (da)
SG (1) SG11202007873VA (da)
WO (1) WO2019170283A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途

Also Published As

Publication number Publication date
WO2019170283A8 (en) 2019-11-07
CA3092907A1 (en) 2019-09-12
CN112533620A (zh) 2021-03-19
AU2019232768B2 (en) 2025-12-18
HUE064471T2 (hu) 2024-03-28
EP3762004B1 (en) 2023-09-13
EP3762004A1 (en) 2021-01-13
AU2019232768A1 (en) 2020-09-03
CN112533620B (zh) 2025-03-28
US20210038661A1 (en) 2021-02-11
SG11202007873VA (en) 2020-09-29
ES2965632T3 (es) 2024-04-16
KR20260089640A (ko) 2026-06-15
RU2020132466A (ru) 2022-04-05
JP2025013934A (ja) 2025-01-28
KR20210031852A (ko) 2021-03-23
RU2020132466A3 (da) 2022-04-05
WO2019170283A1 (en) 2019-09-12
FI3762004T3 (fi) 2023-12-11
JP2021517119A (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
DK3939658T3 (da) Substitueret benzopyrrol og strukturelt relaterede komplementinhibitorer
DK3753937T3 (da) Atr-hæmmer og anvendelse deraf
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3697405T3 (da) Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
EP3761992A4 (en) ARGINASE INHIBITORS
DK3932919T3 (da) Jak-inhibitorforbindelse og anvendelse deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
PT3902803T (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
IL281209A (en) Compounds and formulations for protective coatings
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3752251T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK3658141T3 (da) Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
IL282083A (en) Boron containing pde4 inhibitors
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3643713T3 (da) Heterocykliske kinaseinhibitorer og deres anvendelse